Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine

Assessment of minimal or measurable residual disease (MRD) has emerged as a powerful and predictive tool for outcomes in patients with acute leukemia. There are several methods of measuring MRD, including detection of pathogenic mutations on next-generation genomic profiles and the detection of driver transcripts by real-time quantitative polymerase chain reaction. More commonly, MRD is characterized by highly sensitive multiparameter flow cytometry, which has allowed detection of leukemia cells to a level of 1:104 or 1:106 [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research